Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

<h4>Background</h4> <p>We identified anti-obesity medications withdrawn since 1950 because of adverse drug reactions after regulatory approval, and examined the evidence used to support such withdrawals, investigated the mechanisms of the adverse reactions, and explored the trends...

Descripció completa

Dades bibliogràfiques
Autors principals:	Onakpoya, I, Heneghan, C, Aronson, J
Format:	Journal article
Idioma:	English
Publicat:	BioMed Central 2016

Ítems similars

Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
per: Onakpoya, I, et al.
Publicat: (2017)

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
per: Onakpoya, IJ, et al.
Publicat: (2016)

Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis
per: Onakpoya, I, et al.
Publicat: (2016)

Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
per: Onakpoya, I, et al.
Publicat: (2017)

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
per: Onakpoya, I
Publicat: (2017)

Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: An analysis of justification.
per: Onakpoya, I, et al.
Publicat: (2017)

Pharmacogenetics and adverse drug reactions
per: Ferner, R, et al.
Publicat: (2010)

An agenda for research on adverse drug reactions.
per: Aronson, J
Publicat: (2007)

Adverse drug reactions--no farewell to harms.
per: Aronson, J
Publicat: (2007)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
per: Aronson, J
Publicat: (2008)

Adverse drug reactions: definitions, diagnosis, and management.
per: Edwards, I, et al.
Publicat: (2000)

Adverse drug reactions: keeping up to date.
per: Aronson, J, et al.
Publicat: (2002)

Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems : Arrêts de commercialisation de médicaments post-autorisation : succès de la pharmacovigilance, problèmes réglementaires
per: Aronson, J
Publicat: (2017)

Paradoxical reactions: Under-recognized adverse effects of drugs?
per: Hauben, M, et al.
Publicat: (2006)

National differences in publishing papers on adverse drug reactions.
per: Ferner, R, et al.
Publicat: (2005)

Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.
per: Aronson, J
Publicat: (2013)

Case reports of suspected adverse drug reactions--systematic literature survey of follow-up.
per: Loke, Y, et al.
Publicat: (2006)

Naltrexone‐bupropion (Mysimba®) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
per: Onakpoya, IJ, et al.
Publicat: (2020)

Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions /
per: Aronson, Jeffrey K.
Publicat: (2006)

Adverse Drug Reactions: History, Terminology, Classification, Causality, Frequency, Preventability
per: Aronson, J
Publicat: (2012)

Benefits and harms in pivotal trials of oral centrally acting antiobesity medicines: A systematic review and meta-analysis.
per: Onakpoya, I, et al.
Publicat: (2018)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
per: Talbot, J, et al.
Publicat: (2012)

Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice
per: Talbot, J, et al.
Publicat: (2012)

Joining the DoTS: new approach to classifying adverse drug reactions.
per: Aronson, J, et al.
Publicat: (2003)

Pharmacogenomics of cutaneous adverse drug reactions as implication for precision medicine
per: Chun-Bing Chen
Publicat: (2023-01-01)

Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines.
per: Smith, C, et al.
Publicat: (1996)

Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
per: Aronson, J
Publicat: (2005)

Adverse Drug Reactions of Cardiovascular Classes of Medicines—Data for Bulgarian Population
per: Zornitsa Mitkova, et al.
Publicat: (2024-09-01)

Stephens' detection and evaluation of adverse drug reactions : principles and practice /
per: Talbot, J. C. C., et al.
Publicat: (2012)

A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.
per: McDowell, SE, et al.
Publicat: (2013)

Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.
per: Aronson, J, et al.
Publicat: (2010)

Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials
per: Derry, S, et al.
Publicat: (2001)

Incomplete evidence: The inadequacy of databases in tracing published adverse drug reactions in clinical trials
per: Derry, S, et al.
Publicat: (2001)

Lorcaserin in obesity: minimal benefits and ill-defined harms
per: Onakpoya, I, et al.
Publicat: (2019)

Social Media as a Source of Information for the Detection of Adverse Drug Reactions in Post-Marketing Surveillance: A Review
per: E. K. Nezhurina, et al.
Publicat: (2024-12-01)

Health risks of unknown medicines: evidence from adverse drug reactions in Laos
per: Caillet, C, et al.
Publicat: (2016)

Control of adverse drug reactions in HIV/AIDS antiretroviral treatment with interchangeable medicines
per: M. V. Zhuravleva, et al.
Publicat: (2018-02-01)

Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies
per: Shanshan Liu, et al.
Publicat: (2023-12-01)

Nonsteroidal anti-inflammatory drugs’ adverse drug reactions: 10 years of national database data
per: G. I. Syraeva, et al.
Publicat: (2022-02-01)

Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess
per: Huadong Ke, et al.
Publicat: (2024-10-01)